The third-quarter loss included an expense for impairment of intangible assets. Revenues came in at $4.8 million, up 54.8% year over year, primarily owing to the recognition of an upfront payment received from Eli Lilly LLY in the first quarter of 2019. Notably, in December 2018, Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform. Meanwhile, sales almost came in line with the Zacks Consensus Estimate of $5 million.